Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats

被引:2
作者
An, Jinho [1 ,2 ]
Kong, Hyunseok [2 ,3 ]
机构
[1] Sahmyook Univ, Coll Pharm, Seoul, South Korea
[2] Sahmyook Univ, Coll PADAM Nat Mat Res Inst, Seoul, South Korea
[3] Sahmyook Univ, Coll Anim Biotechnol & Resource, Seoul, South Korea
来源
PLOS ONE | 2022年 / 17卷 / 05期
基金
新加坡国家研究基金会;
关键词
MODEL; DIHYDROTESTOSTERONE; EPIDEMIOLOGY; STRESS; THYMUS; LEVEL; ACID; SIZE;
D O I
10.1371/journal.pone.0268695
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Testosterone undecanoate is a hormone agent with long-acting potential and is used for testosterone replacement therapy for hypogonadism. This study was designed to investigate application of testosterone undecanoate in maintaining high androgen levels for inducing benign prostatic hyperplasia more conveniently than that for testosterone propionate. We conducted two-part studies to determine the optimal dosage and dosing cycle for efficient and stable induction of benign prostatic hyperplasia using testosterone undecanoate. In the injection dosage substudy, single testosterone undecanoate dose (125, 250, 500, 750, or 1000 mg/kg body weight) was administered, and the optimal concentration was determined for 8weeks by measuring changes in testosterone, dihydrotestosterone, and 5-alpha reductase levels. And then, testosterone undecanoate was administered at the optimal dose at intervals of 1, 2, 3, or 4 weeks for 12weeks to induce benign prostatic hyperplasia. The injection dosage substudy showed dose-dependently higher and more stable levels of testosterone in groups administrated testosterone undecanoate than in groups administered testosterone propionate. In the injection cycle substudy, testosterone undecanoate-administered group stably maintained high levels of testosterone, dihydrotestosterone, and 5-alpha reductase compared with testosterone propionate-administered group for the same injection cycle; moreover, the prostate measurements, an important sign of benign prostatic hyperplasia, were significantly increased. Based on these two substudies, we determined the optimal conditions for inducing benign prostatic hyperplasia stably and more conveniently than that for testosterone propionate. This study suggests an extended application of testosterone undecanoate for inducing benign prostatic hyperplasia that can improve research reliability considering the half-life of testosterone as well as injection dosage and concentration.
引用
收藏
页数:13
相关论文
共 36 条
[1]   Treatment of benign prostatic hyperplasia with Croton membranaceus in an experimental animal model [J].
Afriyie, Daniel K. ;
Asare, George A. ;
Bugyei, K. ;
Adjei, Samuel ;
Lin, Jiu-mao ;
Peng, Jun ;
Hong, Zhen-feng .
JOURNAL OF ETHNOPHARMACOLOGY, 2014, 157 :90-98
[2]   Effects of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats [J].
Arruzazabala, Maria de Lourdes ;
Molina, Vivian ;
Mas, Rosa ;
Carbajal, Daisy ;
Marrero, David ;
Gonzalez, Victor ;
Rodriguez, Eduardo .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (07) :995-999
[3]   Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia [J].
Bartsch, G ;
Rittmaster, RS ;
Klocker, H .
EUROPEAN UROLOGY, 2000, 37 (04) :367-380
[4]   Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism:: phase I studies [J].
Behre, HM ;
Abshagen, K ;
Oettel, M ;
Hübler, D ;
Nieschlag, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (05) :414-419
[5]   Testosterone undecanoate:: A useful tool for testosterone administration in rats [J].
Callies, F ;
Kollenkirchen, U ;
von zur Mühlen, C ;
Tomaszewski, M ;
Beer, S ;
Allolio, B .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2003, 111 (04) :203-208
[6]  
Cantlay A., 2015, INNOVAIT ED INSPIR G, V8, P238, DOI [10.1177/1755738014568038, DOI 10.1177/1755738014568038]
[7]   The role of dihydrotestosterone in benign prostatic hyperplasia [J].
Carson, C ;
Rittmaster, R .
UROLOGY, 2003, 61 (04) :2-7
[8]   Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia [J].
Cordaro, Marika ;
Impellizzeri, Daniela ;
Siracusa, Rosalba ;
Gugliandolo, Enrico ;
Fusco, Roberta ;
Inferrera, Antonino ;
Esposito, Emanuela ;
Paola, Rosanna Di ;
Cuzzocrea, Salvatore .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 329 :231-240
[9]   Maintenance of muscle mass in adult male mice is independent of testosterone [J].
Davidyan, Arik ;
Pathak, Suraj ;
Baar, Keith ;
Bodine, Sue C. .
PLOS ONE, 2021, 16 (03)
[10]   Benign prostatic hyperplasia - what do we know? [J].
Devlin, Conor M. ;
Simms, Matthew S. ;
Maitland, Norman J. .
BJU INTERNATIONAL, 2021, 127 (04) :389-399